Cost-Effectiveness Analysis of Antihypertensive Drug Use in Hypertension-Diabetes Mellitus and Hypertension-Heart Failure Inpatients at a Government Hospital in Yogyakarta, Indonesia
- 10.2991/assehr.k.210415.010How to use a DOI?
- Cost-effectiveness analysis, antihypertensive, inpatient, hypertension-diabetes mellitus, hypertension-heart failure
Hypertension and diabetes mellitus are the leading risk factors for cardiovascular diseases, which are increasing rapidly throughout the world. Hypertension is a non-communicable disease that remains a health problem in Indonesia, with a prevalence of up to 34.11% in 2018. This research was intended to identify cost- effective antihypertensive medication for inpatients with hypertension-diabetes mellitus and hypertension-heart failure. The research method used a retrospective cohort design and measured blood pressure (BP) 72 hours after treatment as the outcome of the observation. Based on a payer perspective, the medical expense was calculated from direct medical costs written in billing invoices. The research subjects were inpatients with hypertension-diabetes mellitus and hypertension-heart failure at a government hospital in Yogyakarta, Indonesia. In the cost- effectiveness analysis, Incremental Cost-Effectiveness Ratio (ICER) was calculated by dividing the difference in cost by the difference in the outcome of hypertension treatment.In the antihypertensive medication of hypertension-diabetes mellitus inpatients, angiotensin-receptor blockers/ calciumchannel blockers (ACB-CCB) were found to be more cost-effective than CCB with incremental costs of IDR 191,405/488,864 for every mmHg decrease of systolic/diastolic BP. Meanwhile, in the antihypertensive treatment of hypertension-heart failure inpatients, the combination of angiotensin-converting- enzyme inhibitors (ACEI) and diuretics was more cost-effective than ACEI-CCB (ICERs= IDR 8,303,483/-39,856,718 per mmHg) and ARB (ICERs= IDR 3,627,694/-2,380,075 per mmHg).In conclusion, ARB-CCB is a cost-effective medication for hypertension-diabetes mellitus inpatients, while ACEI-Diuretics offers a cost-effective hypertensive treatment for hypertension-heart failure inpatients.
- © 2021, the Authors. Published by Atlantis Press.
- Open Access
- This is an open access article distributed under the CC BY-NC license (http://creativecommons.org/licenses/by-nc/4.0/).
Cite this article
TY - CONF AU - Faridah Baroroh AU - Andriana Sari AU - Khansa Zakiyatul Laili AU - Dina Putri Permatasari PY - 2021 DA - 2021/04/19 TI - Cost-Effectiveness Analysis of Antihypertensive Drug Use in Hypertension-Diabetes Mellitus and Hypertension-Heart Failure Inpatients at a Government Hospital in Yogyakarta, Indonesia BT - Proceedings of the First International Conference on Health, Social Sciences and Technology (ICoHSST 2020) PB - Atlantis Press SP - 41 EP - 45 SN - 2352-5398 UR - https://doi.org/10.2991/assehr.k.210415.010 DO - 10.2991/assehr.k.210415.010 ID - Baroroh2021 ER -